Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
AIM The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score ( IPSS ) and urodynamic parameters in the treatment of benign prostatic hyperplasia ( BPH ) . Eviprostat was used as a control to study the efficacy of naftopidil . METHODS Forty-nine patients with BPH ( mean age 67.9 + /- 7.8 years ) were involved in the study . Patients were r and omly assigned either to the naftopidil group , which was treated with the alpha-blocker naftopidil ( 50 - 75 mg daily , 36 patients ) , or the eviprostat group , which was treated with phytotherapy ( six tablets of eviprostat daily , 13 patients ) . RESULTS The mean total IPSS , the total storage and voiding symptom scores , and the quality of life score decreased significantly ( P < 0.0001 for each variable ) in the naftopidil group , but not in the eviprostat group . In the naftopidil group , analyses showed significant increases in average and maximum flow rate and bladder capacity at first desire to void ( P < 0.001 , P = 0.001 and P = 0.024 , respectively ) , and significant decreases in the postvoid residual , the percent of residual and the Abrams-Griffiths number ( P = 0.009 , P = 0.008 and P = 0.042 , respectively ) . However , in the eviprostat group , no significant changes were noted in terms of these symptomatic and urodynamic parameters . In the pressure/flow study , an improvement in the International Continence Society nomogram grade was noted in 29 % of the naftopidil group , but in only 16 % of the eviprostat group . Among the 14 patients in the naftopidil group , detrusor overactivity disappeared in 21 % and cystometric capacity increased in 36 % , but no improvement in detrusor overactivity was noted in the eviprostat group . CONCLUSIONS Naftopidil appears to have been effective in this short-term treatment of BPH
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .